A Peek at Ocular Therapeutix's Future Earnings

Ocular Therapeutix OCUL is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.

Analysts estimate that Ocular Therapeutix will report an earnings per share (EPS) of $-0.24.

The announcement from Ocular Therapeutix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

Earnings History Snapshot

In the previous earnings release, the company missed EPS by $0.04, leading to a 4.06% drop in the share price the following trading session.

Here's a look at Ocular Therapeutix's past performance and the resulting price change:

Analysts' Perspectives on Ocular Therapeutix

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ocular Therapeutix.

Analysts have given Ocular Therapeutix a total of 2 ratings, with the consensus rating being Buy. The average one-year price target is $18.0, indicating a potential 69.81% upside.

Comparing Ratings with Competitors

This comparison focuses on the analyst ratings and average 1-year price targets of Harrow, Harmony Biosciences and Supernus Pharmaceuticals, three major players in the industry, shedding light on their relative performance expectations and market positioning.

• As per analysts' assessments, Harrow is favoring an Buy trajectory, with an average 1-year price target of $56.67, suggesting a potential 434.62% upside.
• As per analysts' assessments, Harmony Biosciences is favoring an Buy trajectory, with an average 1-year price target of $52.5, suggesting a potential 395.28% upside.
• The consensus among analysts is an Neutral trajectory for Supernus Pharmaceuticals, with an average 1-year price target of $36.0, indicating a potential 239.62% upside.

Peer Analysis Summary

The peer analysis summary outlines pivotal metrics for Harrow, Harmony Biosciences and Supernus Pharmaceuticals, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

Key Takeaway:

Ocular Therapeutix ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. The company's Consensus rating is not the highest among its peers.

Discovering Ocular Therapeutix: A Closer Look

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix's Economic Impact: An Analysis

Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.

Revenue Growth: Ocular Therapeutix displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.26%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Ocular Therapeutix's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -266.27%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Ocular Therapeutix's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -11.14%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.29%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.2, Ocular Therapeutix adopts a prudent financial strategy, indicating a balanced approach to debt management.

To track all earnings releases for Ocular Therapeutix visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.